Reaction Details |
| Report a problem with these data |
Target | Cytochrome P450 1A2 |
---|
Ligand | BDBM50401421 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | ChEMBL_883348 (CHEMBL2214084) |
---|
IC50 | >10000±n/a nM |
---|
Citation | Bavetsias, V; Crumpler, S; Sun, C; Avery, S; Atrash, B; Faisal, A; Moore, AS; Kosmopoulou, M; Brown, N; Sheldrake, PW; Bush, K; Henley, A; Box, G; Valenti, M; de Haven Brandon, A; Raynaud, FI; Workman, P; Eccles, SA; Bayliss, R; Linardopoulos, S; Blagg, J Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem55:8721-34 (2012) [PubMed] Article |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Cytochrome P450 1A2 |
---|
Name: | Cytochrome P450 1A2 |
Synonyms: | CP1A2_HUMAN | CYP1A2 | CYPIA2 | Cholesterol 25-hydroxylase | Cytochrome P(3)450 | Cytochrome P450 1A | Cytochrome P450 1A2 (CYP1A2) | Cytochrome P450 4 | Cytochrome P450-P3 |
Type: | Enzyme |
Mol. Mass.: | 58423.38 |
Organism: | Homo sapiens (Human) |
Description: | P05177 |
Residue: | 516 |
Sequence: | MALSQSVPFSATELLLASAIFCLVFWVLKGLRPRVPKGLKSPPEPWGWPLLGHVLTLGKN
PHLALSRMSQRYGDVLQIRIGSTPVLVLSRLDTIRQALVRQGDDFKGRPDLYTSTLITDG
QSLTFSTDSGPVWAARRRLAQNALNTFSIASDPASSSSCYLEEHVSKEAKALISRLQELM
AGPGHFDPYNQVVVSVANVIGAMCFGQHFPESSDEMLSLVKNTHEFVETASSGNPLDFFP
ILRYLPNPALQRFKAFNQRFLWFLQKTVQEHYQDFDKNSVRDITGALFKHSKKGPRASGN
LIPQEKIVNLVNDIFGAGFDTVTTAISWSLMYLVTKPEIQRKIQKELDTVIGRERRPRLS
DRPQLPYLEAFILETFRHSSFLPFTIPHSTTRDTTLNGFYIPKKCCVFVNQWQVNHDPEL
WEDPSEFRPERFLTADGTAINKPLSEKMMLFGMGKRRCIGEVLAKWEIFLFLAILLQQLE
FSVPPGVKVDLTPIYGLTMKHARCEHVQARLRFSIN
|
|
|
BDBM50401421 |
---|
n/a |
---|
Name | BDBM50401421 |
Synonyms: | CHEMBL2207503 |
Type | Small organic molecule |
Emp. Form. | C22H23Cl2N7 |
Mol. Mass. | 456.371 |
SMILES | Cc1nn(C)cc1-c1nc2ncc(Cl)c(N3CCN(Cc4ccc(Cl)cc4)CC3)c2[nH]1 |
Structure |
|